ReviewExperimental biology and medicine (Maywood, N.J.)2015
Inosine and hypoxanthine as novel biomarkers for cardiac ischemia: from bench to point-of-care.
Review in Experimental biology and medicine (Maywood, N.J.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 110 citations in OpenAlex.
- Acute aerobic exercise reveals that FAHFAs distinguish the metabolomes of overweight and normal-weight runners.JCI insight · 2022Trial
- Article
- SGLT2 Inhibitors' Effects on Biomarkers of Myocardial Injury: A Systematic Review.Journal of cardiovascular and thoracic research · 2026Review
- Co-culturing hiPSC-cardiomyocytes and cardiac fibroblasts enhances engineered heart tissue structure and function.Stem cells translational medicine · 2026Article
- Heat stress alters metabolic pathways and nitric oxide signaling in keratinocytes under hyperglycemia.Journal of diabetes investigation · 2026Article
- Sixty Years After a Coal Mine Disaster: Serum Metabolomic Profiles in Older Adults with Long-Term Sequelae of Carbon Monoxide Poisoning: A Cross-Sectional Study.Metabolites · 2026Article
- Tumor-driven purinergic signalling promotes RBFOX1 loss and chemotherapy-induced cardiotoxicity.Purinergic signalling · 2026Article
- Article
- Metagenome-assembled genomes reveal microbial signatures and metabolic pathways linked to coronary artery disease.mSystems · 2025Article
- Purine Nucleotide Precursors in Preventing Myocardial Ischemia-Reperfusion Injury.International journal of molecular sciences · 2025Review
- Investigating the Cytoprotective Mechanisms of the Tardigrade Damage Suppressor (Dsup) Protein in Human Cells Under Hypoxic Stress.International journal of molecular sciences · 2025Article
- Serum metabolic profiling in rheumatic heart disease and degenerative aortic stenosis.Scientific reports · 2025Article
- Tumour initiated purinergic signalling promotes cardiomyocyte RBFOX1 degradation and cardiotoxicity from DNA damaging anticancer agents.Nature communications · 2025Article
- COScientific reports · 2025Article
- Article
- Early Metabolomic Profiling as a Predictor of Renal Function Six Months After Kidney Transplantation.Biomedicines · 2024Article
- Discovery of Hypoxanthine and Inosine as Robust Biomarkers for Predicting the Preanalytical Quality of Human Plasma and Serum for Metabolomics.Analytical chemistry · 2024Article
- Article
- Broadcasters, receivers, functional groups of metabolites, and the link to heart failure by revealing metabolomic network connectivity.Metabolomics : Official journal of the Metabolomic Society · 2024Article
- Plasma metabolomic and lipidomic profiles accurately classify mothers of children with congenital heart disease: an observational study.Metabolomics : Official journal of the Metabolomic Society · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac ischemia associated with acute coronary syndrome and myocardial infarction is a leading cause of mortality and morbidity in the world. A rapid detection of the ischemic events is critically important for achieving timely diagnosis, treatment and improving the patient's survival and functional recovery. This minireview provides an overview on the current biomarker research for detection of acute cardiac ischemia. We primarily focus on inosine and hypoxanthine, two by-products of ATP catabolism. Based on our published findings of elevated plasma concentrations of inosine/hypoxanthine in animal laboratory and clinical settings, since 2006 we have originally proposed that these two purine molecules can be used as rapid and sensitive biomarkers for acute cardiac ischemia at its very early onset (within 15 min), hours prior to the release of heart tissue necrosis biomarkers such as cardiac troponins. We further developed a chemiluminescence technology, one of the most affordable and sensitive analytical techniques, and we were able to reproducibly quantify and differentiate total hypoxanthine concentrations in the plasma samples from healthy individuals versus patients suffering from ischemic heart disease. Additional rigorous clinical studies are needed to validate the plasma inosine/hypoxanthine concentrations, in conjunction with other current cardiac biomarkers, for a better revelation of their diagnostic potentials for early detection of acute cardiac ischemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.